# Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

> **NCT00002985** · PHASE3 · COMPLETED · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** daunorubicin hydrochloride
- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00002985
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-11
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002985, "Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00002985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*